CEP
FOLD

Chicago Equity Partners’s Amicus Therapeutics FOLD Stock Holding History

Chicago Equity Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-41,705
Closed -$627K – 844
2018
Q1 		$627K Buy
41,705
+9,800
+31% +$149K 0.02% 570
2017
Q4 		$459K Hold
31,905
– – 0.01% 632
2017
Q3 		$481K Buy
+31,905
New +$422K 0.02% 623

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chicago Equity Partners's FOLD Position: Q2 2018 in Review

Chicago Equity Partners sold out of Amicus Therapeutics (FOLD) in Q2 2018, closing a stake of 41,705 shares — an estimated $627K sold.

Chicago Equity Partners first reported a position in FOLD in Q3 2017 and held it in 3 quarters. The position peaked at $627K in Q1 2018. 200 funds tracked by Wall St. Rank hold FOLD as of Q2 2018.

  • Chicago Equity Partners reported no remaining Amicus Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Chicago Equity Partners sold 41,705 Amicus Therapeutics shares in Q2 2018, an estimated $627K.
  • Chicago Equity Partners first reported a position in Amicus Therapeutics in Q3 2017 and held it in 3 quarters.
  • Chicago Equity Partners's Amicus Therapeutics position peaked at $627K in Q1 2018.
  • 200 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2018.

Based on Chicago Equity Partners's 13F filing for Q2 2018, filed 10 Aug 2018.